Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 10/20 | 0.36 |
| ▸ | GRPR | P30550 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31448364 | 1.00 | OPRD1 (0.41) | OPRD1CASP3CASP7BACE1GRPR | |
| SCHEMBL30738394 | 0.90 | BACE1 (0.41) | CASP3CASP7BACE1CTSD | |
| SCHEMBL29853431 | 0.90 | BACE1 (0.41) | CASP3CASP7BACE1CTSD | |
| SCHEMBL31448410 | 0.88 | FNTA (0.38) | CASP3CASP7BACE1CTSD | |
| SCHEMBL29853203 | 0.88 | FNTA (0.38) | CASP3CASP7BACE1CTSD | |
| SCHEMBL20397445 | 0.85 | FNTA (0.37) | CASP3CASP7BACE1CTSD | |
| SCHEMBL31049654 | 0.85 | CTSD (0.38) | CASP3CASP7BACE1CTSD | |
| SCHEMBL20397476 | 0.85 | FNTA (0.37) | CASP3CASP7BACE1CTSD | |
| SCHEMBL30129742 | 0.85 | ECE1 (0.43) | BACE1 | |
| SCHEMBL30988398 | 0.83 | ACE (0.33) | OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709854-A1 | IMPROVED CRISPR/CAS GUIDE RNA (GRNA) | Evox Therapeutics Limited (GB) | 2026-03-18 | — | — | EP | disclosed |
| US-20260034239-A1 | LOADED EXTRACELLULAR VESICLE | UNIV OXFORD INNOVATION LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| US-20250288695-A1 | TSPAN2 AS SCAFFOLD PROTEIN FOR ENGINEERED EXTRACELLULAR VESICLES | EVOX THERAPEUTICS LIMITED (GB) | 2025-09-18 | — | — | US | disclosed |
| EP-4561536-A1 | LOADED EXTRACELLULAR VESICLE | Oxford University Innovation Limited (GB) | 2025-06-04 | — | — | EP | disclosed |
| EP-4519427-A1 | TSPAN2 AS SCAFFOLD PROTEIN FOR ENGINEERED EXTRACELLULAR VESICLES | Evox Therapeutics Limited (GB) | 2025-03-12 | — | — | EP | disclosed |
| US-20250057781-A1 | ENGINEERED EXTRACELLULAR VESICLES WITH IMPROVED CARGO DELIVERY | EVOX THERAPEUTICS LIMITED (GB) | 2025-02-20 | — | — | US | disclosed |
| WO-2024231575-A1 | IMPROVED CRISPR/CAS GUIDE RNA (GRNA) | EVOX THERAPEUTICS LIMITED (GB) | 2024-11-14 | — | — | WO | disclosed |
| EP-4452334-A1 | ENGINEERED EXTRACELLULAR VESICLES WITH IMPROVED CARGO DELIVERY | Evox Therapeutics Limited (GB) | 2024-10-30 | — | — | EP | disclosed |
| WO-2024023504-A1 | LOADED EXTRACELLULAR VESICLE | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023213979-A1 | TSPAN2 AS SCAFFOLD PROTEIN FOR ENGINEERED EXTRACELLULAR VESICLES | EVOX THERAPEUTICS LIMITED (GB) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023117378-A1 | ENGINEERED EXTRACELLULAR VESICLES WITH IMPROVED CARGO DELIVERY | EVOX THERAPEUTICS LIMITED (GB) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034239-A1 | LOADED EXTRACELLULAR VESICLE | EXOSC10, EXOSC9, SUMO1 | OPRD1 2565/4885CASP3 3727/4885CASP7 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.